Cardiovascular disease remains the leading cause of death worldwide, and aggressive lipid management remains one of the most effective ways to reduce risk. The latest ACC/AHA dyslipidemia guideline updates (released March 2026) reinforce aggressive LDL-C reduction, emphasize earlier risk assessment, and expand the role of non-statin therapies.
For busy clinicians in primary care, cardiology, and internal medicine, here are the Top 10 key takeaways from the latest ACC/AHA dyslipidemia recommendations.
1. “Lower is Better” for LDL-C
The newest guidance continues to emphasize aggressive LDL-C lowering, particularly for patients with established ASCVD.
Key targets now commonly emphasized:
• <70 mg/dL for high-risk ASCVD
• <55 mg/dL for very high-risk patients
• Consider even lower thresholds when multiple events occur
Large outcome trials continue to show that each 39 mg/dL reduction in LDL lowers major cardiovascular events by ~20–25%.
2. Risk Stratification is Critical
The guidelines emphasize better risk stratification before initiating therapy.
Important risk-enhancing factors include:
• Family history of premature ASCVD
• Chronic kidney disease
• Chronic inflammatory diseases
• Metabolic syndrome
• Elevated Lp(a)
• Elevated ApoB
These factors can justify earlier or more aggressive lipid therapy even when traditional risk scores appear borderline.
3. Coronary Artery Calcium (CAC) Remains a Powerful Decision Tool
For patients with intermediate ASCVD risk, CAC scoring remains a valuable tool.
Typical interpretation:
• CAC = 0: statin therapy may be deferred in selected patients
• CAC 1–99: consider statin therapy
• CAC ≥100: statin therapy strongly recommended
CAC continues to help personalize treatment decisions and improve patient adherence.
4. Statins Remain First-Line Therapy
Despite new therapies, statins remain the foundation of lipid management.
Recommended intensity:
High-intensity statins reduce LDL by ≥50%
Examples include:
• Atorvastatin 40–80 mg
• Rosuvastatin 20–40 mg
Moderate-intensity statins remain appropriate for many primary prevention patients.
5. Non-Statin Therapies Are Used Earlier
The updated approach increasingly emphasizes combination therapy when LDL goals are not met.
Stepwise approach commonly recommended:
- Maximally tolerated statin
- Add ezetimibe
- Add PCSK9 inhibitor if LDL still above target
Early combination therapy is becoming more common in very high-risk ASCVD patients.
6. PCSK9 Inhibitors Are Now Mainstream
PCSK9 inhibitors have become an important tool for high-risk patients.
These agents can lower LDL by ~60% and significantly reduce cardiovascular events.
Common agents include:
• Evolocumab
• Alirocumab
They are particularly useful in:
• Familial hypercholesterolemia
• Statin intolerance
• Persistent LDL elevation despite statins
7. Inclisiran Provides Twice-Yearly LDL Reduction
Inclisiran represents a newer therapeutic approach using siRNA technology.
Key advantages:
• LDL reduction ~50%
• Dosed every 6 months
• Potential for improved adherence
This therapy is increasingly considered for patients who struggle with daily medications.
8. Lipoprotein(a) Screening is Recommended at Least Once
The guideline emphasizes the importance of measuring Lp(a) at least once in adulthood.
Elevated Lp(a) is:
• A genetically determined risk factor
• Associated with premature ASCVD
• Under-recognized in routine practice
Identifying elevated Lp(a) may justify earlier statin therapy or more aggressive LDL targets.
9. ApoB Can Help Clarify Risk
In patients with metabolic syndrome, diabetes, or high triglycerides, ApoB measurement may provide a more accurate assessment of atherogenic particle burden.
ApoB is particularly useful when:
• Triglycerides are elevated
• LDL appears normal but risk is high
• Patients have insulin resistance
10. Lifestyle Remains the Foundation
Even with powerful lipid-lowering therapies, lifestyle modification remains essential.
Clinicians should continue emphasizing:
• Mediterranean-style diet
• Regular aerobic exercise
• Weight reduction when appropriate
• Smoking cessation
Lifestyle changes improve lipid levels while also reducing overall cardiometabolic risk.
Why These Updates Matter for Primary Care
Primary care clinicians manage the majority of lipid disorders. The updated recommendations highlight a shift toward:
• Earlier intervention
• More aggressive LDL lowering
• Expanded use of combination therapy
• Better identification of high-risk patients
Understanding these changes is essential to preventing myocardial infarction, stroke, and cardiovascular death.
Learn the Latest Guideline Updates at CME Travel Academy
Keeping up with evolving guidelines can be challenging. At CME Travel Academy conferences, we provide evidence-based reviews of the latest clinical guidelines, including updates in:
• Chronic Coronary Disease including Dyslipidemia
• Diabetes
• Heart Failure
• Chronic Kidney Disease
• Resistant Hypertension
• Obesity
• COPD
• Depression and Dementia
Our conferences are designed specifically for busy clinicians, with morning-only sessions so you can enjoy the city, food, culture, and experiences in the afternoons.
Join physicians, nurse practitioners, and physician assistants from across the country to learn the latest guideline updates while traveling to incredible destinations.
Explore upcoming conferences and register today.